Dose-ranging and cohort-expansion study of monalizumab(IPH2201) in advanced gynecologic malignancies:A trial of the Canadian Cancer Trials Group (CCTG):IND221.

CONCLUSIONS: Monalizumab 10 mg/kg IV q 2 weekly is well tolerated in patients with pre-treated gynecologic cancers. Short term disease stabilization was observed. Future studies should assess combinations with other agents including immunotherapeutics.
PMID: 31308062 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - July 14, 2019 Category: Cancer & Oncology Authors: Tinker AV, Hirte HW, Provencher DM, Butler MO, Ritter H, Tu D, Azim HA, Paralejas P, Grenier N, Hahn SA, Ramsahai J, Seymour L Tags: Clin Cancer Res Source Type: research